Avalo Therapeutics (AVTX) Other Non-Current Assets (2014 - 2026)

Avalo Therapeutics (AVTX) has 13 years of Other Non-Current Assets data on file, last reported at $183000.0 in Q1 2026.

• Quarterly Other Non-Current Assets rose 39.69% year-over-year to $183000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $183000.0 (up 39.69% YoY) and the FY2025 annual result came in at $210000.0, up 60.31% from the prior year.
• Other Non-Current Assets fell to $183000.0 in Q1 2026, from $210000.0 in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $227000.0 in Q1 2022 to a low of $131000.0 in Q4 2022.
• A 5-year average of $162235.3 and a median of $131000.0 in 2022 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets plunged 42.29% — and 2025, when it surged 60.31%.
• Tracing AVTX's Other Non-Current Assets over 5 years: stood at $131000.0 in 2022, then changed by 0.0% to $131000.0 in 2023, then changed by 0.0% to $131000.0 in 2024, then surged by 60.31% to $210000.0 in 2025, then retreated by 12.86% to $183000.0 in 2026.
• The last three Other Non-Current Assets figures came in at $183000.0 (Q1 2026), $210000.0 (Q4 2025), and $210000.0 (Q3 2025), per Business Quant data.